Clinical trials
Liver Diseases clinical trials
Below are recruiting liver diseases clinical trials, each written for real people, not researchers. We’re tracking 438 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07370103Recruiting
Predicting low blood pressure in liver disease patients after anesthesia
This study uses an ultrasound to measure blood flow in the neck's main artery to see if it can predict a dangerous drop in blood pressure after you are put to sleep for surgery. It is for adult patients with chronic liver disease who are having planned surgery.
CairoAges 18 years+ - NCT07488975RecruitingPhase 1
Microbial therapy for MASLD trial
This trial tests a new microbial therapy for MASLD, a type of fatty liver disease. It aims to improve liver health by targeting gut microbes.
TaipeiAges 18–70 - NCT07592013Enrolling by invitation
Ancestry Supplements for Fatty Liver Disease
This study tests whether a special supplement (made from cacao, nopal, and crickets) can help improve fatty liver disease in people with excess body fat. Fatty liver disease happens when fat builds up in the liver, and this trial investigates whether these natural ingredients can reduce that buildup.
Guadalajara, GuadalajaraAges 18–60 - NCT07280143Recruiting
MASLD risk in breast or colorectal cancer survivors
This study looks at whether breast or colorectal cancer survivors are more likely to develop a liver condition called MASLD (fatty liver disease not caused by alcohol). It uses blood tests, imaging, and possibly an MRI to check liver health.
BernAges 18 years+ - NCT06861478RecruitingPhase 2
PPIs for bleeding varices in liver disease
This trial tests whether proton pump inhibitors (PPIs) can help people with cirrhosis who are hospitalized for variceal bleeding. It looks at whether PPIs reduce complications during the hospital stay.
Monterrey, Nuevo LeónAges 18 years+ - NCT06632457RecruitingPhase 3
Survodutide for NASH/MASH cirrhosis: a phase 3 trial
This study tests an investigational drug called survodutide for people with a type of fatty liver disease (NASH or MASH) that has progressed to cirrhosis. The goal is to see if it can improve liver health.
Peoria, ArizonaAges 18 years+ - NCT07313007Recruiting
Gut bacteria chemicals in fatty liver disease
This study looks at whether the natural chemicals made by your gut bacteria from the food you eat could affect liver fat and health. If you have MASLD (a fatty liver condition), researchers want to measure these gut-produced substances to better understand the disease.
Pierre-BéniteAges 18–80 - NCT07459504RecruitingPhase 2
Smart diets for kids with fatty liver disease
This study compares different diet plans to see which works best to reduce fat in the liver of children and teens with MASLD (a type of fatty liver disease). If your child drinks sugary beverages often and has certain health risks like being overweight or having high cholesterol, this trial may help find a healthy eating plan that works.
Grand Rapids, MichiganAges 11–17 - NCT06968234Recruiting
Liver disease breath test study
This study uses a special breath test to learn about chronic liver disease. If you have liver disease or cirrhosis, you may be able to help by providing a breath sample.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07684326RecruitingPhase 2/Phase 3
Can dapagliflozin help liver cirrhosis with fluid buildup? (Phase 2/3 randomized trial)
This trial tests a diabetes pill (dapagliflozin) to see if it helps people with liver cirrhosis and fluid buildup (ascites). The goal is to improve fluid balance and possibly reduce hospital stays.
GizaAges 18 years+ - NCT07530809Recruiting
Time-Restricted Eating for Fatty Liver Disease
This study tests whether eating within a limited time window each day can improve fatty liver disease (a buildup of fat in the liver). If you have moderate-to-advanced fatty liver disease and are overweight, this trial might help you learn if changing when you eat—rather than what you eat—can reduce liver fat and improve your health.
Homburg, SaarlandAges 18–75 - NCT07382349Recruiting
Decision support tools for fatty liver disease
This study tests electronic tools to help doctors identify and care for patients with steatotic liver disease (fatty liver). If you have risk factors like diabetes or elevated liver enzymes, this trial may help improve your care.
Nashville, TennesseeAges 18 years+ - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Birmingham, AlabamaAges 18–80 - NCT04634643Recruiting
Studies what causes fatty liver in teens
This study looks at why “nonalcoholic fatty liver disease” happens in teenagers and how it develops. It may help doctors better predict and prevent liver problems in children, even if there isn’t a new drug for you to take.
New Haven, ConnecticutAges 12–18 - NCT03855917RecruitingPhase 4
Short 4-week hepatitis C treatment for early liver disease
This trial tests whether a very short 4-week course of two hepatitis C drugs (sofosbuvir and glecaprevir-pibrentasvir) can cure hepatitis C in people with early-stage liver disease. The goal is to see if a shorter treatment works as well as longer ones.
Darlinghurst, New South WalesAges 18 years+ - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT07707778Enrolling by invitationPhase 4
Tirzepatide for Weight and Aging in People with HIV
This trial tests whether a weight-loss medicine called tirzepatide can slow biological aging and improve metabolism in people with HIV who are already on effective treatment. It may help you reduce weight and possibly reverse some signs of aging.
TaipeiAges 18 years+ - NCT03151473Recruiting
Study of adults with fatty liver and NASH over time
This is a long-term study that follows adults who are being managed for fatty liver (NAFL) or NASH to learn how these conditions change over time. It may help researchers better understand what to expect and how care decisions could be improved.
Hong KongAges 18 years+ - NCT03190538Recruiting
Study of fatty liver inflammation in Chinese children
This trial looks at nonalcoholic steatohepatitis (fatty liver with inflammation) in children. It is meant to test whether a new approach can help improve this liver problem without being caused by alcohol or other known liver diseases.
BeijingAges 1–18 - NCT03569826Recruiting
Study for primary biliary cholangitis and autoimmune hepatitis
This study is for people diagnosed with primary biliary cholangitis or autoimmune hepatitis. It aims to learn more about these autoimmune liver conditions and may help guide better care in the future.
Calgary, AlbertaAges 18 years+ - NCT03572465Recruiting
Ultrasound tests to diagnose fatty liver inflammation
This study checks whether special ultrasound measurements can help diagnose nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. You may need a liver biopsy as part of routine care, and you may also be scanned with MRI to support the study tests.
Montreal, QuebecAges 18 years+ - NCT03811236Recruiting
Test cold exposure to activate body fat and reduce liver fat
This study tests whether controlled cold exposure can activate “brown fat” and affect liver fat buildup. It may help people with excess liver fat, measured on imaging, but it has several health and medication exclusions.
ViennaAges 18–50 - NCT04111692Recruiting
Watching foam treatment for cysts in autosomal polycystic disease
This study follows adults with inherited kidney and/or liver cysts that are causing symptoms to see how a foam sclerotherapy procedure may help and what outcomes happen over about a year. You may be eligible if you have a few sizable, specific-type cysts and can safely attend follow-up visits.
Rochester, MinnesotaAges 18–100
Hear when a new Liver Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for liver diseases?
- Yes. Clin2 currently lists 438 recruiting liver diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a liver diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a liver diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.